Efpia Model Consortium Agreement

This agreement regulates all of the following activities and the document is available for verification in the online submission tool. As third party contributors, you grant the consortium`s public partners within ESCulab unlicensed access rights to the background (“Program IP”) that you have on the program necessary to perform the work on your screening program. The DESCA model is widespread among universities and research institutes. The DESCA initiative, launched by major Horizon 2020 interest groups and developed in collaboration with the PUBLIC service community, aims to reconcile the interests of all categories of participants: large and small companies, universities, public research institutes and NGOs. DESCA is a simple and comprehensive consortium agreement, free from unnecessary complexity in both content and language. For targeted programmes: programme name, target, genetic identifier and mechanism of action; for non-target programmes: programme name, biological sample, trigger, reaction of interest, time and method of quantification. This information will be passed on to other consortium partners, but your name and organization will not be disclosed. If a unionized partner wishes to obtain rights to use the research for your program, these rights should be negotiated on fair and reasonable terms, in accordance with the Third Party Contributor Agreement. These conditions may include delays in granting access rights to research, which may amount to six (6) years from the publication of the LHQ`s results.

Do you need more information on preparing and signing grant agreements? Watch this Horizon 2020 webinar for coordinators of successful proposals. Where a programme is defined as a screening programme which relates to a biological objective specific to a pathogen as it is on the World Health Organisation`s list of neglected tropical diseases (see current list under www.who.int/neglected_diseases/diseases/en/) or malaria disease, and whose choice is the status of “programme for neglected diseases”, all consortium partners have agreed to irrevocably waive their milestone payment entitlements.. . . .